Altogether, the evidence supports that HME represses the SRC/STAT3/survivin signaling axis to inhibit cell viability and clonogenicity of bladder cancer cells, consequently exerting cytotoxicity. This evidence concerns the gene BIRC5 and urinary bladder cancer.